The company declared that EC approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal.
Incyte declared on Friday that the European Commission has approved its Zynyz for yet another rare cancer, marking the drug’s second approval in the region.
The company declared that the commission approved Zynyz in combination with carboplatin and paclitaxel for adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal.
The drug was previously approved in Europe for the first-line treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma.
Get updates to this developing story directly on Stocktwits.
Leave a Reply